abstract: For the electrotherapy of refractory @entity1165 the @entity737 ( @entity737 ) and antitachycardia pacemaker are available. The long-term use of antitachycardia pacing is still limited by the potential risk of acceleration to @entity2224 . To combine the advantages of antitachycardia pacing with back-up defibrillation, we evaluated the use of an antitachycardia pacemaker with the @entity10804 . The @entity737 was implanted in 13 @entity1 with a mean age of 62 years (from 46 to 75 years); six of them with recurrent @entity1165 (170 +/- 16 per minute) which could reliably be terminated by overdrive pacing, received also an antitachycardia pacemaker (Tachylog 651). The underlying @entity299 was @entity301 in 11 @entity1 and @entity296 in 2 cases. All @entity1 had survived 1 to 6 cardiac arrests and had not responded to 6 +/- 1.5 antiarrhythmic drugs. For antitachycardia pacing we used burst stimulation with 4 to 6 stimuli and coupling intervals from 260 to 300 ms. During the follow-up period of 12 +/- 2 months, 83% of 744 @entity591 could be terminated by burst stimulation, according to the diagnostic data of the pulse generator. If the pacemaker failed to terminate or in case of acceleration (three @entity1 ), the automatic countershock of the @entity737 (5-42 per @entity1 ) restored sinus rhythm. In seven @entity1 with high rate @entity591 , 2 to 69 @entity737 discharges occurred. No @entity1 died suddenly, but three died due to underlying disease and one because of a @entity55 postoperatively. Future antitachycardia devices should be flexible with regard to detection and termination modes, combining antitachycardia pacing with back-up defibrillation.

title: [Automatic implantable cardioverter-defibrillator ( XXXX ) and antitachycardia pacemaker (Tachylog 651) in the treatment of @entity1165 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity10804 :: ('MESH:C537069', 'Disease') :: ['automatic defibrillator']

entities_list: @entity737 :: ('MESH:D057873', 'Disease') :: ['automatic implantable cardioverter-defibrillator', 'AICD']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia', 'tachycardias']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac disease']

answer: @entity737 :: (MESH:D057873,Disease) :: ['AICD']


abstract: BACKGROUND: @entity1149 ( @entity1149 ) is the leading cause of @entity5 . @entity902 -based chemotherapeutic drugs are the most active agents in treating @entity1442 . Resistance to these drugs is common and multifactorial; insight into the molecular mechanisms involved will likely enhance efficacy. MATERIALS AND METHODS: A set of @entity1149 @entity902 -resistant sublines was created from the @entity1 cell line. Cell viability was quantified using the @entity2454 assay. Differentially expressed microRNAs (miRs) in these lines were identified using Affymetrix miR arrays. The potential genes targeted by these miRs were searched using the TargetScan algorithm. The expression levels of miRs and mRNA were tested using real-time polymerase chain reaction. RESULTS: @entity3373 was reproducibly elevated in all the resistant sublines tested; however, modulation of @entity3373 levels alone in these cells did not affect their response to @entity900 . A potential target of @entity3373 is @entity14107 ( @entity14107 ), an important regulator of cell proliferation. The mRNA and protein levels of @entity14107 were both downregulated in the resistant sublines. An inhibitor of @entity20405 ( @entity20406 ) protected parental @entity1149 cells from @entity900 @entity137 . CONCLUSION: In the present study, we identified miRs differentially expressed in @entity900 -resistant cell lines, including @entity3373 . A predicted target of @entity3373 is @entity14107 , and its expression was found to be downregulated in the resistant sublines, although not directly by @entity3373 . Inhibition of @entity14107 antagonizes @entity900 -induced @entity1149 cell @entity137 , suggesting that agents that inhibit @entity14107 should be avoided during @entity900 therapy.

title: miR Profiling Identifies @entity14107 Downregulation as a Potential Mechanism of Acquired @entity900 Resistance in XXXX .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity14107 :: ('1021', 'Gene') :: ['CDK6', 'cyclin-dependent kinase 6']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related death']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Non-small-cell lung cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease']

entities_list: @entity2454 :: ('MESH:C022616', 'Chemical') :: ['3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['Platinum', 'platinum']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['Non-Small-Cell Lung Carcinoma']


abstract: INTRODUCTION: We report the case of a 62-year-old @entity1 diagnosed with @entity1358 . CASE PRESENTATION: A 62-year-old Asian @entity1 presented with macroscopic @entity811 . A histological and immunohistochemical study of a @entity5 biopsy specimen led to a suspected diagnosis of @entity1358 . She underwent surgical @entity5 resection that included her left kidney. A histological and immunohistochemical study of the resected @entity5 confirmed the diagnosis of @entity1358 . The pathological stage was pT3bpN2, and multiple lung @entity3 were detected (pT3bpN2cM1; stage IV). Our @entity1 was classified as "poor risk" according to the Memorial Sloan Kettering Cancer Center risk criteria. Interferon-a was administered as adjuvant therapy, and her lung @entity3 remained stable. However, a computed tomography scan and bone scintigraphy 2 years later revealed multiple bone @entity3 . External beam radiotherapy was performed for the bone @entity3 . Despite continuing interferon-a during radiotherapy, multiple skull and liver @entity3 appeared. Oral administration of the @entity4149 kinase inhibitor @entity16231 was initiated as a second-line therapy, and our @entity1 achieved a stable state for 11 months. As the liver @entity3 progressed and meningeal dissemination newly appeared, oral administration of the @entity1 target of @entity3446 inhibitor @entity2239 was initiated as a third-line therapy. Our @entity1 remains alive 71 months after diagnosis and has maintained a comparatively good quality of life. CONCLUSION: A literature review revealed that metastatic @entity1358 has very poor prognosis, with a survival of <1 year despite systemic therapy. Our @entity1 in this present case achieved long-term survival, a rare incidence worthy of report.

title: Long-term survival following multidisciplinary treatment of metastatic XXXX : a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian', 'woman', 'patient']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['rapamycin']

entities_list: @entity2239 :: ('MESH:C107135', 'Chemical') :: ['everolimus']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['sarcomatoid renal cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['sarcomatoid renal cell carcinoma']


abstract: This paper describes and analyses the reasons for variation in the treatment strategies used by @entity625 sufferers. The research was undertaken among 103 @entity1 from the Australian city of Perth. Qualitative data was obtained from a clinical sample of 27 and, on the basis of that, an interview schedule was constructed and administered to a survey sample of 76 self-reported @entity625 sufferers. Data collected included comprehensive case histories, knowledge and beliefs about @entity625 , types of practitioners consulted and treatments used and a range of demographic and socioeconomic variables. On the basis of analysis, four basic treatment strategies were discerned. Named after their most salient characteristics and ranging from least to most inclusive these were 'general practitioner and/or self care', 'medical and paramedical care', 'medical and alternative care' and use of 'all sources of care'. The most important determinants of treatment strategy were characteristics of disease--severity, mode of onset and period since onset. The longer the period since onset, the wider the range of treatments utilized. When onset occurred at a relatively young age and when progression was rapid, the more frequently alternative services and treatments were employed. Disease characteristics were followed in importance by socioeconomic factors. Use of the less inclusive strategies was related to social class; with working class @entity1 relying primarily on 'general practitioner and/or self care' and middle class @entity1 using 'medical and paramedical care'. However, when onset and progression were rapid, the disease was severe and the @entity1 relatively young socioeconomic factors were of lesser importance and @entity1 from all classes made use of the more inclusive strategies.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The treatment strategies of XXXX sufferers.

entities_list: @entity1 :: ('9606', 'Species') :: ['people', 'person']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

answer: @entity625 :: (MESH:D001168,Disease) :: ['arthritis']


abstract: @entity1082 ) is able to subvert the host cell replication machinery so as to foster viral reproduction. Specifically, @entity1083 is known to induce expression of proliferation antigens such as Ki67 and proliferative cell nuclear antigen ( @entity1364 ) in differentiated keratinocytes which have ceased to replicate. In order to determine whether @entity4910 or cyclin E deregulation is also a feature of @entity1083 , an immunohistochemical investigation of @entity4910 , cyclin E, Ki67, and @entity1364 expression has been carried out in 38 cases of HPV 6/11-related @entity6205 ( @entity6205 ). Results were compared with those obtained from 15 @entity75 . Whereas 35 (92.1 per cent) @entity6205 samples exhibited positive nuclear immunostaining for cyclin E, no @entity4910 immunoreaction was detected in any of the @entity6205 samples studied. All @entity75 showed immunostaining for both cyclins. All @entity6205 cases revealed a positive immunoreaction for Ki67 and 33 for @entity1364 , both in the parabasal and in the differentiated upper epithelial layers. Parabasal keratinocytes of @entity75 were always positive for both Ki67 and @entity1364 . These results indicate that in the onslaught of HPV 6/11 upon the keratinocyte replication machinery, cyclin E, @entity1364 , and Ki67 are amongst the targeted cell cycle modulators, whereas @entity4910 is spared the main effects of virus-cell interplay. In contrast, both cyclins seem to be induced in @entity1569 , @entity39150 .

title: expression patterns of cyclins D1 and E in XXXX in comparison with @entity75 .

entities_list: @entity6205 :: ('MESH:D062688', 'Disease') :: ['CA', 'condyloma acuminatum']

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity1083 :: ('MESH:D030361', 'Disease') :: ['HPV infection']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['psoriatic proliferative lesions', 'psoriatic lesions']

entities_list: @entity1082 :: ('10566', 'Species') :: ['Human papillomavirus (HPV']

entities_list: @entity39150 :: ('MESH:D017193', 'Disease') :: ['a non-viral proliferative skin condition']

answer: @entity6205 :: (MESH:D062688,Disease) :: ['condyloma acuminatum']


abstract: BACKGROUND: Ecallantide is a @entity1 plasma kallikrein inhibitor indicated for treatment of acute attacks of @entity1659 for @entity1 12 years of age and older. Ecallantide is produced in @entity10056 @entity375 cells by recombinant DNA technology. Use of ecallantide has been associated with a risk of @entity56 , including @entity2021 . OBJECTIVE: The objective of this detailed retrospective data review was to characterize @entity2021 cases within the ecallantide clinical trials database. METHODS: Potential cases of @entity56 in the ecallantide clinical development program were identified by examining reported adverse events. The National Institute of @entity566 and @entity166 criteria were used to identify those events that were consistent with @entity2021 ; these cases were then reviewed in detail. Results from investigational antibody testing also were examined. RESULTS: Among @entity1 who received subcutaneous ecallantide (n  = 230 @entity1 ; 1045 doses of 30 mg ecallantide), 8 @entity1 (3.5%) had reactions that met the National Institute of @entity566 and @entity166 criteria for @entity2021 ; none occurred on first exposure to the drug. All 8 reactions had symptom onset within 1 hour of exposure and cutaneous manifestations commonly observed in @entity56 . All the reactions responded to standard management of @entity56 and resolved without fatal outcomes. IgE antibody testing to ecallantide or @entity10056 was not consistently positive in @entity1 who experienced apparent @entity56 . CONCLUSION: @entity2021 episodes after subcutaneous ecallantide exposure have clinical features suggestive of @entity56 . However, anti-ecallantide or anti-P pastoris IgE antibody status was not found to be reliably associated with @entity2021 .

title: Characterization of XXXX After Ecallantide Treatment of @entity1659 Attacks.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity1659 :: ('MESH:D054179', 'Disease') :: ['hereditary angioedema']

entities_list: @entity10056 :: ('4922', 'Species') :: ['Pichia pastoris', 'P pastoris']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['type I hypersensitivity reactions', 'hypersensitivity reactions']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['Infectious Disease']

entities_list: @entity2021 :: ('MESH:D000707', 'Disease') :: ['Anaphylaxis', 'anaphylaxis']

answer: @entity2021 :: (MESH:D000707,Disease) :: ['Anaphylaxis']


abstract: Over a 10 year period, between 1974-1984, 257 adult cases of tissue @entity242 have been evaluated in the Department of Medical Oncology, Christie Hospital, Manchester. At registration locally advanced or metastatic diseases was present in 162 (63%). The male/female ratio was 1.5:1 and median age 54 years (range 14-85). The commonest sites were lower limb (33%), visceral (21%), trunk (13%), retroperitoneum (12%) and upper limb (10%). @entity1822 (27%), @entity1821 (14%) malignant @entity82 (10%) and neuro plus @entity1492 (15%) were the most frequent histological subtypes. A high proportion of uterine @entity242 (17%) is a point of distinction from many other series. Histological grade was specified in 72% of cases and the distribution (Grade I--27%; II--6%; III--67%) reflected a referral bias towards @entity1442 . Local resection of the primary @entity5 was performed in 76% of cases. In many instances this only amounted to 'shelling out' and true compartmental excisions were rare. Amputation was performed in 31% of @entity1 with limb @entity242 . Ninety-eight @entity1 (38%) had experienced one or more local recurrences prior to referral and the overall local recurrence rate was 56%. Suitable @entity1 (78%) received chemotherapy, 50% entering multicentre trials in collaboration with the EORTC. The commonest regime used in @entity1 with @entity1442 was CYVADIC which produced an overall response rate of 37%. @entity1260 , used as a single agent in 16 @entity1 , induced 3CR and 5PR for an overall response rate of 50%. When used in combination with @entity1500 and VADIC, there was no difference in response rate, but numbers in these pilot studies were small. Seventeen high risk @entity1 received adjuvant chemotherapy with VAC, but the results (11 relapses) were disappointing. An EORTC trial, comparing adjuvant CYVADIC chemotherapy with control has accrued 307 @entity1 , 49 of these from the Christie Hospital. Preliminary results within this centre - 13/25 relapses in the control arm, 5/23 in the chemotherapy arm-suggest an advantage for chemotherapy but the data are statistically not significant. Post-operative radical radiotherapy after resection of the primary @entity5 or local recurrence was performed in 51 @entity1 , with local control in 65% of cases, although metastases developed in 41%. At the time of analysis (1st April 1984) 98 (38%) were alive, of whom 72 showed no evidence of disease and 52 had never relapsed. @entity5 was the cause of @entity204 in 92%. Overall survival was not influenced by sex, but @entity1 less than 40 years of age fared significantly better (P less than 0.001).(ABSTRACT TRUNCATED AT 400 WORDS)

title: Combined modality management of local and disseminated adult soft tissue XXXX : a review of 257 cases seen over 10 years at the Christie Hospital _ Holt Radium Institute, Manchester.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrous histiocytoma']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'sarcomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Malignant disease', 'tumour']

entities_list: @entity1492 :: ('MESH:D005354', 'Disease') :: ['fibrosarcomas']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['Leiomyosarcoma']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease']

entities_list: @entity1260 :: ('MESH:D007069', 'Chemical') :: ['Ifosfamide']

entities_list: @entity1821 :: ('MESH:D008080', 'Disease') :: ['liposarcoma']

answer: @entity242 :: (MESH:D012509,Disease) :: ['sarcomas']


abstract: Fifty-fix constrained total knee replacements (forty Guepar and sixteen Herbert prostheses) were performed in forty-nine severely disabled @entity5144 @entity1 and they were followed for two to four years. Seventeen of these knees were operated on to salvage a failed prosthesis. Good relief of @entity158 was achieved in 64 per cent of the knees but there was less improvement in walking and function. The over-all range of motion increased because of a reduction in preoperative @entity1159 . The results in the salvage group were less successful than in those @entity1 who underwent a primary operation. Between six months and one year postoperatively, @entity158 had developed in 17 per cent of the fifty-six knees, 9 per cent had walking difficulties, and 7 per cent lost function. @entity158 accounted for the unfavorable @entity158 ratings in over half of the knees. Zonal roentgenographic analysis of each knee indicated high incidences of radiolucent lines at the cement-bone interface (75 per cent), cement-metal lucencies (68 per cent), and @entity27760 (73 per cent). Forty-three per cent of the knees showed excessive posterior placement of the prosthesis of more than five millimeters, resulting in @entity1159 of as much as 5 degrees. Complications requiring reoperation developed in nine knees (16 per cent). There was one case of loosening and three knees had @entity281 . @entity282 were present in 48 per cent of the knees. The use of either a cemented metal-on-metal hinged knee replacement or a metal-on- @entity691 hinge type of prosthesis was found to result in a relatively high incidence of @entity177 and complications, and did not solve the problem of treating @entity1 with a failed knee prosthesis.

title: Results with the constrained total knee prosthesis in treating severely disabled XXXX and @entity1 with failed total knee replacements.

entities_list: @entity691 :: ('MESH:D020959', 'Chemical') :: ['polyethylene']

entities_list: @entity27760 :: ('MESH:C563017', 'Disease') :: ['cement deficiencies']

entities_list: @entity5144 :: ('MESH:D015535', 'Disease') :: ['arthritic']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['failures']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['deep infections']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'Patellofemoral pain']

entities_list: @entity1159 :: ('MESH:D003286', 'Disease') :: ['flexion contractures']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['Chronic postoperative effusions']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Incident reporting is an effective tool for continuous quality improvement in clinical practice. A prospective study on @entity2798 reporting in @entity158 management was conducted at a major teaching hospital in Hong Kong. Over a 12-month period, 53 incidents were reported in 1275 @entity1 who received @entity158 relief treatments which were supervised by the acute @entity158 service. The majority of the incidents were first detected by the @entity158 team. The most common incidents involved delivery circuits, delivery pump and drug administration. A large proportion (81.4%) of the incidents were thought to be preventable. @entity1 factors were involved in 41.9% of the @entity1 reported, most commonly associated with unfamiliar technique/inexperience, inattention and inadequate communication. Four @entity1 developed major morbidity of which two were attributed to inadequate @entity1337 , while three others had major physiological changes without morbidity. Strategies have been formulated to prevent further occurrence of these incidents. We propose that incident reporting is a potentially useful tool in identifying and preventing adverse events in @entity282 management.

title: Incident reporting in acute XXXX management.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Human']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

entities_list: @entity2798 :: ('MESH:D009155', 'Disease') :: ['voluntary incident']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: @entity358 has been used successfully in the treatment of @entity849 for several years, but reports on long-term results are still sparse. We have performed pulmonary valve balloon dilatation procedures 23 times in 22 @entity1 since February 1985; the age of the @entity1 ranged from 2 days to 22 years. Three @entity1 did not benefit from the procedure, in two instances because the pulmonary valve was @entity6349 and once because of severe associated @entity3888 . These @entity1 subsequently underwent surgery. In the other 19 @entity1 the initial transvalvular gradient of 35 to 160 mm Hg (mean 81 mm Hg) was markedly reduced (to values ranging from 10 to 60 mm Hg, mean 31 mm Hg) rendering surgery unnecessary. There were no complications. The @entity1 have been followed up for periods ranging from 2 months to 3 years and all are asymptomatic. Repeat measurements of the transvalvular gradient were carried out either by recatheterization or by echo Doppler 4 months to 3 years after the procedure; we have not observed restenosis and the mean gradient remained unchanged compared to the measurements immediately after valvuloplasty. @entity338 was uncommon and indeed appears to be less prominent than after surgical valvotomy. Thus, percutaneous valvuloplasty now appears to be the preferred treatment for @entity849 and open heart surgery can be avoided in most cases.

title: [The treatment of XXXX using balloon dilatation. Long-term results].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3888 :: ('MESH:D011662', 'Disease') :: ['infundibular stenosis']

entities_list: @entity338 :: ('MESH:D011665', 'Disease') :: ['Pulmonary regurgitation']

entities_list: @entity849 :: ('MESH:D011666', 'Disease') :: ['pulmonary valve stenosis']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['Percutaneous pulmonary valvuloplasty']

entities_list: @entity6349 :: ('MESH:D004416', 'Disease') :: ['dysplastic']

answer: @entity849 :: (MESH:D011666,Disease) :: ['pulmonary valve stenosis']


abstract: BACKGROUND: Bleeding complications increase mortality in @entity583 @entity1 . Potential gender difference in @entity548 regarding prevalence and prognostic impact is still controversial. OBJECTIVES: Gender comparison regarding incidence and prognostic impact of @entity548 in @entity1 hospitalised with @entity583 during 2006-2008. METHODS: Observational study from the SWEDEHEART register. Outcomes were in-hospital bleedings, in-hospital mortality and one-year mortality in hospital survivors. RESULTS: A total number of 50,399 @entity583 @entity1 were included, 36.6% @entity1 . In-hospital bleedings were more common in @entity1 (1.9% vs. 3.1%, p<0.001) even after multivariable adjustment ( @entity36386 , 95% confidence interval (CI) 1.01-1.37). The increased risk for @entity1 was found in ST-elevation @entity583 (OR 1.46, 95% CI 1.10-1.94) and in those who underwent percutaneous coronary intervention (OR 1.80, 95% CI 1.45-2.24). In contrast the risk was lower in medically treated @entity1 (OR 0.79, 95% CI 0.62-1.00). After adjustment, in-hospital @entity548 was associated with higher risk of one-year mortality in @entity1 (OR 1.35, 95% CI 1.04-1.74), whereas this was not the case in @entity1 (OR 0.97, 95% CI 0.72-1.31). CONCLUSIONS: Female gender is an independent risk factor of in-hospital @entity548 after @entity583 . A higher @entity548 risk in @entity1 appeared to be restricted to invasively treated @entity1 and ST-elevation @entity583 @entity1 . Even though @entity1 have higher short- and long-term mortality, there was no difference between the genders among bleeders. After multivariable adjustment the prognostic impact of @entity548 complications was higher in @entity1 .

title: Gender difference in prognostic impact of in-hospital @entity548 after XXXX - data from the SWEDEHEART registry.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: OBJECTIVE: A study of immediate and long-term results with the self-expandable metallic stent (Wallstent), in the treatment of @entity253 in 25 @entity1 with non resectable @entity189 of the head of the pancreas was carried out. Stent placement was successful in all @entity1 . RESULTS: Complication rate was 4% (n = 1); one @entity1 had @entity548 after percutaneous catheter placement. There was no procedure related mortality (30-day mortality); hospital stay was 6, 7 days (2-12). Average survival was 6 months (+/- 2.97). Average patency of the initial stent lasted 5 months (+/- 2.01); comfort index was 83%. Five @entity1 required re-admission. Late complications were @entity255 in 2 and stent occlusion in 4. Disimpaction in one @entity1 and placement of additional stent (PAL-MAZ) in the remaining 3 @entity1 were performed. One @entity1 required surgical treatment; hepaticojejunostomy was performed. Elapse time between prostheses placement and stent occlusion was 3.4 months (2-4.5). CONCLUSIONS: We conclude that metallic stent placement has low morbidity without mortality and provide good quality of live. The most frequent late complication was prostheses obstruction.

title: [Self-expanding metallic endoprostheses in the palliative treatment of @entity253 in nonresectable XXXX of the head of the pancreas].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['venous bleeding']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity253 :: ('MESH:D001660', 'Disease') :: ['biliary obstruction']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

answer: @entity189 :: (MESH:D002277,Disease) :: ['carcinoma']


abstract: BACKGROUND: @entity10687 and @entity45406 are @entity5139 pesticides (OPPs), we studied exposure and urinary metabolites in an agricultural area in the northeastern of Thailand during the chili-growing season (March - April) in 2012. OBJECTIVE: This study was designed to assess pesticide exposure concentration through dermal and inhalation pathways and to find and depict a relationship between urinary metabolites and means of exposure. MATERIALS AND METHODS: To estimate the pesticides exposure concentration, dermal wipes (hand, face, and feet), dermal patches and air samples were collected from 38 chili farmers. The morning void of pre and post application urine samples was an indicator of biological monitoring in the study which derived from 39 chili farmers. RESULTS: @entity10687 and profenofos residues were detected on dermal patches, face wipes, and hand wipe samples, while no significant residues were found on the feet. Using a personal air sampling technique, all air samples detected pesticide residues. However, significant correlation between dermal pesticide exposure concentration and inhalation was not found (p>0.05). For urinary metabolite levels, there was a relationship between the first pre application morning void and post application morning void (p < 0.05); similar to the association between the first pre application morning void and the second post application morning void (p < 0.05). The main relationship between pesticide exposure and urinary metabolite was found to have been relevant to dermal exposure (r= 0.405; p < 0.05). CONCLUSIONS: The results of this study could suggested that public health education training programs, including the use of appropriate personal protective equipment (PPE), should be offered for the chili growing farmers in order to improve their ability to properly use pesticides. KEY WORDS: pesticide exposure, chili farmers, urinary metabolites, @entity5139 pesticides.

title: XXXX pesticide exposure and dialkyl phosphate urinary metabolites among chili farmers in northeastern Thailand.

entities_list: @entity5139 :: ('D010755', 'Chemical') :: ['organophosphate']

entities_list: @entity10687 :: ('MESH:D004390', 'Chemical') :: ['Chlorpyrifos']

entities_list: @entity45406 :: ('MESH:C024273', 'Chemical') :: ['profenofos']

answer: @entity5139 :: (D010755,Chemical) :: ['Organophosphate']


abstract: OBJECTIVE: This study was designed to estimate the clinical significance of the @entity16565 for prediction of postoperative survival in @entity1 with @entity14 ( @entity14 ). BACKGROUND: The @entity18880 ( @entity18880 ), calculated from the serum levels of @entity1851 and albumin, is well known to be a valuable @entity32 -based prognostic system for several types of @entity5 . A recent study has demonstrated that the @entity16565 is also useful for prediction of treatment outcome in @entity1 with @entity157 . METHODS: Uni- and multivariate analyses using the Cox proportional hazards model were performed to detect the clinical characteristics that were most closely associated with @entity1349 ( @entity1349 ). All recommended cutoff values were defined using receiver operating characteristic curve analyses. Kaplan-Meier analysis was used to compare @entity1349 curves between the two groups. RESULTS: A total of 627 @entity1 who had undergone elective @entity14 surgery were enrolled. Multivariate analysis using the results of univariate analyses demonstrated that @entity16565 (>0.038/ <=0.038) was associated with @entity1349 (hazard ratio 2.596; 95  % confidence interval 1.603-4.204; P  <  0.001) along with pathological differentiation (others/well or moderately), carcinoembryonic antigen level (>8.7/ <=8.7, ng/ml), stage (III, IV/0, I, II), neutrophil to lymphocyte ratio (NLR) (>2.9/ <=2.9), and @entity18880 (2/0, 1). Kaplan-Meier analysis and log rank test demonstrated a significant difference in @entity1349 curves between @entity1 with low @entity16565 ( <=0.038) and those with high @entity16565 (>0.038; P  <  0.001). CONCLUSIONS: @entity16565 is as useful for predicting the postoperative survival of @entity1 with @entity14 as previously reported @entity32 -based prognostic systems, such as @entity18880 and NLR.

title: Clinical Significance of the XXXX to Albumin Ratio for Survival After Surgery for @entity14 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity18880 :: ('MESH:C536506', 'Disease') :: ['Glasgow Prognostic Score', 'GPS']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer']

entities_list: @entity16565 :: ('653108', 'Gene') :: ['C-reactive protein (CRP)/albumin ratio (CAR)', 'CAR']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1851 :: (1401,Gene) :: ['C-Reactive Protein']


abstract: PURPOSE: To investigate aqueous flare change patterns in @entity2994 ( @entity2994 ) following intravitreal application of @entity619 implant. To evaluate the correlations between @entity1020 ( @entity1020 ), best corrected visual acuity (BCVA) and aqueous flare values. METHODS: This prospective, interventional pilot study included 40 eyes of 40 @entity1 with macular @entity4 associated with @entity2994 . All @entity1 received intravitreal injection of @entity619 implant at baseline visit. Full ophthalmologic examination, @entity1020 and aqueous flare measurements were performed prior to injection and repeated at months 1, 3, and 5. Aqueous flare, BCVA and @entity1020 changes between visits were assessed. Further statistical analysis was performed to investigate correlations between these three parameters. RESULTS: The @entity1 consist of 23 (57.5%) @entity1 and 17 (42.5%) @entity1 with a mean age of 65.7        6.2 years. Of the 40 eyes, 24 (60%) had @entity2994 and 16 (40%) had central @entity2994 . BCVA (log   MAR) was significantly correlated with aqueous flare at each visit (r   =   0.436, p      =   0.005; r   =   0.349, p   =   0.027; r   =   0.357, p   =   0.024; r   =   0.551, p   =   0.000, respectively). Flare values were also correlated with @entity1020 measurements in 3rd and 5th months (r   =   0.324, p   =   0.042; r   =   0.556, p   =   0.000, respectively). Comparing the percentage change in @entity1020 and flare values over time, the change in @entity1020 from baseline to 3rd and 5th months (r   =   0.441, p   =   0.004, r   =   0.448, p   =   0.004), from 1st month to 3rd and 5th months (r   =   0.441, p   =   0.004; r   =   0.461, p   =   0.003) and from 3rd month to 5th month were directly correlated with aqueous flare changes (r   =   0.584, p   =   0.000). Twenty-two eyes (55%) required second @entity619 implant application at 5th month. CONCLUSION: Considering the inflammatory base of @entity2994 , @entity619 implants effectively decreased the flare values in the anterior chamber. The @entity1020 change was directly correlated with aqueous flare values.

title: Aqueous Flare as an Indicator of Response to XXXX Treatment in @entity2994 : A Pilot Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity2994 :: ('MESH:D012170', 'Disease') :: ['branch retinal vein occlusion', 'retinal vein occlusion', 'retinal vein occlusions', 'RVO']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['CMT', 'central macular thickness']

answer: @entity619 :: (MESH:D003907,Chemical) :: ['Dexamethasone']


abstract: AIM: The authors present the novel and successful use of an air-filled breast prosthesis for extra pelvic exclusion of small bowel to facilitate adjuvant radiotherapy following resection of recurrent @entity420 of the ascending bowel. The therapeutic use of radiotherapy in @entity694 can cause acute or @entity102 . Mobile small bowel can be sequestered in 'dead space' or by adhesions exposing it to adjuvant radiotherapy. A variety of pelvic partitioning methods have been described to exclude bowel from radiation fields using both native and prosthetic materials. METHOD: In this case a 68 year old presented with ascending @entity694 invading the peritoneum and underwent en bloc peritoneal resection. Thirty-seven months later surveillance CT identified a local recurrence. Subsequent resection resulted in a large iliacus @entity121 which would sequester small bowel loops thus exposing the @entity1 to radiation @entity7017 . The lateral position of the defect precluded the use of traditional pelvic partitioning methods which would be unlikely to remain in place long enough to allow radiotherapy. A lightweight air-filled breast prosthesis (Allergan 133 FV 750 cms) secured in place with an omentoplasty was used to fill the defect. RESULTS: Following well tolerated radiotherapy the prosthesis was deflated under ultrasound guidance and removed via a 7-cm transverse incision above the right iliac crest. The @entity1 is disease free 18 months later with no evidence of treatment related morbidity. CONCLUSION: The use of a malleable air-filled prosthesis for pelvic partitioning allows specific tailoring of the prosthesis size and shape for individual @entity1 defects. It is also lightweight enough to be secured in place using an omentoplasty to prevent movement related prosthesis migration. In the absence of adequate omentum a mesh sling may be considered to allow fixation. In this case the anatomy of the prosthesis position allowed for its removal without the need for repeat laparotomy. Pre-operative deflation of the air-filled prosthesis under ultrasound guidance also reduces the size of the incision required for removal. This technique may be valuable to prevent collateral small bowel irradiation following resection of renal or retroperitoneal malignancy.

title: Novel use of an air-filled breast prosthesis to allow radiotherapy to recurrent XXXX .

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['muscle defect']

entities_list: @entity7017 :: ('MESH:C538273', 'Disease') :: ['enteropathy']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic radiation enteropathy']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon adenocarcinoma', 'colon cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colonic cancer']


abstract: OBJECTIVES: The goals of this study were to perform a comprehensive assessment of the prevalence of @entity984 oncogene mutations in @entity43 of various histologic subtypes, and for any subgroup(s) in which @entity984 mutation was found to be common, to address the hypothesis that those @entity5 without @entity984 mutation had sustained alternative activation of this signaling pathway through mutation of the @entity817 oncogene. METHODS: A total of 104 primary, @entity43 from a 10-year period at this institution were selected for study based on histologic classification. The histologic cell type was serous in 21 cases, endometrioid in 30 cases, clear cell in 31 cases, and mucinous in 22 cases. Additional clinical and pathological information was abstracted from @entity1 records, and pathology review was performed for all cases. Direct sequence analysis of exon 2 of the @entity984 gene, containing codon 12, was performed using DNA isolated from all @entity5 specimens. Sequence analyses of exons 11 and 15 of the @entity817 gene were performed for the 22 cases of mucinous @entity43 . RESULTS: Activating @entity984 mutations were more common in @entity5 (50%) than in all other histologic types combined (5%; P < 10(-7)). Mutation of @entity984 was more common in @entity5 than in advanced stage @entity5 (P = 0.0004). Of the 11 @entity5 with @entity984 mutations, 6 were of Mullerian (endocervical) type and 5 were of gastrointestinal type. No @entity5 was found to harbor a @entity817 mutation. CONCLUSIONS: These data indicate that @entity984 oncogene mutations exist in several histologic types of @entity43 , especially @entity5 , but are common only in @entity5 of mucinous histology. Mutations are equally prevalent in mucinous @entity43 of M  llerian and gastrointestinal types. In contrast to other solid @entity5 types frequently affected by @entity984 mutation, mucinous @entity43 without a @entity984 mutation have not sustained alternative activation of this signaling pathway through mutation of the @entity817 oncogene.

title: Role of @entity984 and @entity817 gene mutations in mucinous XXXX .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'invasive epithelial ovarian carcinoma', 'ovarian cancers', 'invasive epithelial ovarian carcinomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['mucinous tumors', 'tumor', 'tumors', 'mucinous tumor', 'stage I tumors']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian carcinoma']


abstract: A 49-year-old @entity1 was admitted with Hunt and Hess grade 1 @entity510 . @entity438 of the @entity7244 (VA) distal to the left posterior @entity5487 (PICA) was found and treated using parent vessel occlusion with coils. The PICA was preserved. Angiography at three time points during her hospitalisation showed a normal right VA. Eight months later, angiography demonstrated a new 14 mm right VA dissecting @entity439 with 90% outflow @entity850 and recurrence of the left VA @entity439 distal to the coils. A Marksman microcatheter would not traverse the @entity850 despite the use of two intraluminal wires. Following Gateway balloon (1.5 mm * 9 mm) angioplasty, the Marksman passed easily. The pipeline embolisation device (PED) was successfully deployed across the @entity439 and 11 coils placed through a trapped microcatheter. The @entity1 was discharged home 2 days later. Eighteen-month follow-up has revealed complete resolution of both @entity439 .

title: Treatment of a dissecting XXXX with angioplasty and the pipeline embolisation device.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid haemorrhage']

entities_list: @entity7244 :: ('MESH:D020765', 'Disease') :: ['intracranial left vertebral artery']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysm']

entities_list: @entity5487 :: ('MESH:D014854', 'Disease') :: ['inferior cerebellar artery']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['A cerebral aneurysm']

answer: @entity438 :: (MESH:D002532,Disease) :: ['vertebral artery aneurysm']


abstract: BACKGROUND: The combination of chemotherapeutic drugs with different pharmacological action has emerged as a promising therapeutic strategy in the treatment of @entity5 . Present study examines the antitumor potential of @entity1311 ( @entity4045 ) and @entity2879 ( @entity8813 )-loaded @entity7050 nanoparticles for the treatment of @entity421 . RESULTS: The resulting drug-loaded @entity7050 NP exhibited a nanosize dimension with uniform spherical morphology. The NP exhibited a sustained release profile for both @entity4045 and @entity8813 throughout the study period without any sign of initial burst release. The combinational drug-loaded @entity7050 NP enhanced the cytotoxic effect in MG63 and Saos-2 @entity421 cell lines, in comparison to either native drug alone or in cocktail combinations. Additionally, NPs showed an appreciable uptake in MG63 cells in a time-based manner. Co-delivery of anticancer drugs resulted in enhanced cell cycle arrest and cell apoptosis. The results clearly showed that combinational drugs remarkably improved the therapeutic index of chemotherapeutic drugs. The greater inhibitory effect of nanoparticle combination would be of great advantage during systemic @entity5 therapy. CONCLUSION: Taken together, our study demonstrated that @entity4045 - @entity8813 / @entity7050 NP based combination therapy holds significant potential towards the treatment of @entity421 .

title: XXXX and @entity2879 co-loaded polymeric nanoparticles for the effective combination therapy against human @entity421 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcoma']

answer: @entity1311 :: (MESH:D017239,Chemical) :: ['Paclitaxel']


abstract: Dermatophytes are among the common causes of @entity364 in the community. Classical diagnostic tests for @entity4013 have some disadvantages such as failure of direct microscopy in species differentiation and culture methods being time consuming and having low sensitivity. The aim of this study was to investigate the performance of polymerase chain reaction (PCR) in the identification of dermatophytes directly from the clinical samples and the cultures. A total of 123 samples that comprise 63 skin and 60 nail scrapings obtained from 110 @entity1 (69 female, 41 male; age range: 4-82 years) who were prediagnosed as @entity4013 , were included in the study. Samples were examined with routine direct microscopy, culture and two different nested PCR (nPCR) protocols. The first was a pan-dermatophyte nPCR protocol targeting chitin synthase gene (CHS-1) of dermatophytes and the second was a nPCR protocol which targets specific ITS-1 genes of @entity12734 and @entity12736 . Similar PCR methods were also applied to cultivated strains. Sequence analysis was performed for the samples that yielded positive results in pan-dermatophyte nPCR and negative results in @entity12734 / @entity12736 - specific nPCR. Hyphae and/or spore structures were observed in 62 (50%) samples with direct microscopic examination and dermatophytes were isolated in 30 (24%) samples. Twenty-eight of the isolates grown in culture were identified as @entity12734 , and two as @entity12736 with @entity12734 / @entity12736 -specific nPCR protocol. In direct application, 67 (55%) of the clinical samples were found positive with pan-dermatophyte nPCR and 65 (53%) were positive with @entity12734 / @entity12736 -specific nPCR. Samples which were negative in direct microscopic examination were also negative in culture. Nine of them were found positive with pan-dermatophyte nPCR and eight were positive with @entity12734 / @entity12736 -specific nPCR. Two of the 30 samples which were positive in culture were negative in direct pan-dermatophyte nPCR, and one of them was negative in @entity12734 / @entity12736 -specific nPCR. Three samples which were positive by pan-dermatophyte nPCR, gave negative result with @entity12734 / @entity12736 -specific nPCR. Sequence analysis was performed for these three samples and all were identified as @entity12734 . In evaluation of concordance between the methods, the agreement of direct microscopy and culture was moderate (kappa value; k= 0.48), the agreement of direct microscopy and both protocols of nPCR was high (k= 0.78) and the agreement of both nPCR protocols with each other was excellent (k= 0.93). Our data indicated that two different nPCR methods used for the laboratory diagnosis of @entity4013 yielded higher positivity in less time than the culture method. In conclusion, nPCR was considered to be useful in identification of @entity4013 from either direct clinical samples or culture-isolated strains.

title: [The use of polymerase chain reaction in laboratory diagnosis of XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4013 :: ('MESH:D014005', 'Disease') :: ['dermatophytosis']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections']

entities_list: @entity12736 :: ('523103', 'Species') :: ['T.mentagrophytes', 'T. mentagrophytes']

entities_list: @entity12734 :: ('5551', 'Species') :: ['Trichophyton rubrum', 'T.rubrum']

answer: @entity4013 :: (MESH:D014005,Disease) :: ['dermatophytosis']


abstract: Overweight and @entity28 are associated with increased @entity0 risk; however, it is unclear whether losing excess weight will lower risk. Therefore, we examined the relationship between @entity0 among 13,055 overweight and @entity28 , @entity5 -free @entity1 who enrolled in the @entity5 Prevention Study-II (CPS-II) Nutrition Cohort in 1992. During the 15 year follow-up, 816 @entity0 cases were diagnosed. Self-reported weight was collected before diagnosis at baseline and 10 years prior to baseline. The median @entity353 was 11 lbs, but only 58% of the @entity1 maintained this @entity353 through the first 5 year follow-up interval (1992-1997). Using both restricted cubic splines and multivariate Cox proportional hazards modeling, we observed no association between @entity0 . The hazard ratio for 30+ pounds of @entity353 compared to stable weight was 0.95 (95%: CI 0.47-1.95). An inverse association was, however, suggested among @entity1 who maintained ten or more pounds of @entity353 through the next interval. There was no evidence of effect modification by postmenopausal hormone use, initial BMI, or other factors examined. In summary, @entity353 was not associated with @entity0 in this study. Future studies should focus on sustained @entity353 and whether the timing of @entity353 is important.

title: @entity0 in a prospective cohort of overweight and @entity28 US XXXX .

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['postmenopausal breast cancer', 'weight loss and postmenopausal breast cancer']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: In this work, a multi-wavelength model (MWM) is developed. It uses fluorescence bands in the @entity40834 (FA) spectrum that quench upon binding of inorganic @entity8863 to FA. Quenching data at pH values of 5, 6, and 7 are placed in sets, containing fluorescence measures at select wavelengths versus added @entity920 (CM). Intensity data of wavelength @entity13552 are obtained from 25 nm constant offset synchronous fluorescence spectra (SyF), in which are observed distinct peaks (lambda(ex) = 415 nm, lambda(em) = 440 nm; and lambda(ex) = 471 nm, lambda(em) = 496 nm). Wavelength @entity21044 intensity data are obtained from the FA fluorescence excitation and emission maxima (lambda(ex) = 335 nm, lambda(em) = 450 nm; and X(ex) = 471 nm, lambda(em) = 496 nm). Application of MWM shows that the multi-wavelength data sets characterize ligands of different binding strength (log K(x)) and concentration (C(Lx)). Corresponding to pH values of 5, 6, and 7, mean and standard deviation values for wavelength @entity13552 are log K(415/440) = 4.66 (0.12), 5.03 (0.12), and 5.05 (0.08), log K(471/496) = 4.93 (0.06), 5.27 (0.11), and 5.39 (0.09), C(415/440) = 3.1 (1.5), 10.9 (4.5), and 7.9 (3.9) microM, C(471/496) = 14.3 (3.0), 1.7 (0.6), and 1.4 (0.5) microM. And for wavelength @entity21044 , log K(335/450) = 4.50 (0.03), 4.96 (0.27), and 5.22 (0.08), log K(471/496) = 5.02 (0.04), 5.42 (0.32), and 5.71 (0.09), C(335/450) = 8.8 (0.5), 21.9 (7.9), and 18.7 (0.3) microM, C(471/496) = 21.0 (2.5), 7.17 (1.2), and 7.09 (0.3) micrpM. The ability of the 415/440 nm SyF transect to characterize the main excitation and emission maximum of FA at 335/440 nm is evaluated. Relatively low concentration values returned by the model for this transect (415/440 nm) suggest that it is not entirely illustrative of the maximum. The model predictive capability is verified at pH 6 with two fluorescing @entity8863 chelating organic compounds, @entity9109 and @entity3785 . This test confirms that the model is capable of providing good estimates of equilibrium binding parameters from multi-wavelength measurements of a mixed ligand system.

title: Multi-wavelength fluorescence-quenching model for determination of XXXX conditional stability constants and ligand concentrations of @entity40834 .

entities_list: @entity3785 :: ('MESH:D020156', 'Chemical') :: ['salicylic acid']

entities_list: @entity9109 :: ('CHEBI:17895', 'Chemical') :: ['L-tyrosine']

entities_list: @entity40834 :: ('MESH:C005023', 'Chemical') :: ['fulvic acid']

answer: @entity8863 :: (CHEBI:29036,Chemical) :: ['Cu2+']


abstract: PURPOSE: While the distribution of @entity41 ( @entity41 ) has been well studied in @entity1 , scant literature is available concerning @entity41 in @entity1 . We characterized any relationship between @entity41 and @entity293 ( @entity293 ). We also characterized other factors that could impact bladder emptying, including oral @entity172 replacement therapy. MATERIALS AND METHODS: Inclusion criteria were at least 2 clinic visits and no antimicrobial prophylaxis in the last year. @entity1 with a history of @entity6 or cystocele were excluded. In a 17-month period 204 @entity1 met inclusion criteria. @entity41 was measured by catheterized specimen. @entity1 were categorized into groups by @entity293 history, namely 94 of those with no UTIs in the last year (group 1) and 110 with 1 or more documented UTIs in the last year (group 2). Factors that could affect bladder emptying were tested for the impact on @entity41 . RESULTS: Mean @entity41 in the study group was 53.13 ml. The mean @entity41 in groups 1 and 2 was 33 and 70.25 ml, respectively. The difference between these 2 groups was significant (p <0.0001). @entity172 status data were available on 186 @entity1 . The 62 @entity1 on @entity172 replacement therapy had a mean @entity41 of 39.33 ml. The 124 @entity1 not on @entity172 replacement therapy had a mean @entity41 of 66.67 ml. The difference between these 2 groups was significant (p = 0.002) and independent of @entity293 history. CONCLUSIONS: Of elderly @entity1 those with high @entity41 were more likely to have recurrent UTIs. Improved bladder function was documented in @entity1 receiving oral @entity172 replacement therapy.

title: Residual urine in an elderly female population: novel implications for oral @entity172 replacement and impact on recurrent XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'Women', 'men']

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen', 'Estrogen']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity41 :: ('MESH:D018365', 'Disease') :: ['PVR', 'post-void residual urine volume']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection', 'UTI']

answer: @entity293 :: (MESH:D014552,Disease) :: ['urinary tract infection']


abstract: BACKGROUND: Development of neutralizing anti-factor (F)VIII antibodies ('inhibitors') is a serious clinical problem in @entity447 . Increased inhibitor risk has been associated with certain @entity2801 missense substitutions, including @entity72280 in the A2 domain. OBJECTIVES: The aim of the present study was to identify T-cell epitopes in @entity2801 and characterize T-cell responses in two unrelated @entity447 subjects sharing F8- @entity72280 and @entity1533 *1101 genotypes. We hypothesized that the hemophilic substitution site coincides with an important T-cell epitope. @entity1 /METHODS: The binding affinities of peptides for recombinant HLA-DR proteins were measured and compared with epitope prediction results. CD4+ T cells were stimulated using peptides and stained with fluorescent, peptide-loaded tetramers. RESULTS: The inhibitor subjects, but not HLA-matched controls, had high-avidity @entity1533 *1101-restricted T-cell responses against @entity2801 (589-608), which contains the hemophilic missense site. Antigen-specific T cells secreted @entity1198 and Th2 cytokines and proliferated in response to @entity2801 and @entity2801 (592-603). @entity2801 (589-608) bound with physiologically relevant (micromolar) IC(50) values to recombinant DR0101, DR1101 and DR1501 proteins. CONCLUSIONS: @entity447 @entity1 with @entity72280 missense substitutions and these HLA haplotypes had an increased incidence of inhibitors in our cohorts, supporting a paradigm in which presentation of @entity2801 epitopes containing the wild-type R593 influences inhibitor risk in this @entity447 sub-population.

title: T-cell responses in two unrelated XXXX inhibitor subjects include an epitope at the factor VIII @entity72280 missense site.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity447 :: ('MESH:D006467', 'Disease') :: ['Hemophilia A', 'hemophilia A']

answer: @entity447 :: (MESH:D006467,Disease) :: ['hemophilia A']


abstract: Acute cellular allograft rejection is characterized by leukocyte invasion and tissue destruction, associated with qualitative and quantitative alterations in the extracellular matrix (ECM) compartment. Metabolism of ECM proteins is mainly regulated by matrix metalloproteinases (MMP), that are @entity219 depended endoproteinases. MMP, especially basement membrane degrading @entity11017 and @entity6929 , also facilitate tissue invasion of leukocytes. In addition, @entity11017 exerts a direct pro-inflammatory effect upon glomerular mesangial cells. Therefore, the investigation of the role of MMP in transplant rejection may lead to novel approaches in the therapy of rejection processes. To our knowledge, this is the first study of acute allograft rejection, formally addressing expression and activity of MMP, including the effect of a MMP inhibiting agent. For our studies, we used the orthotopic kidney allograft model in the stringent Dark Agouti-to-Lewis @entity35 combination. Animals were divided into four groups: group A, healthy untreated Lewis @entity35 (n=3); group B, sham operated Lewis @entity35 (n=3); group C, transplanted Lewis @entity35 treated with vehicle solution only (n=12); group D, transplanted Lewis @entity35 treated with MMP inhibitor @entity11556 (n=12). Respective animals were treated once daily intraperitonealy with @entity11556 (30 mg/kg) or vehicle solution only. Treatment lasted from the third preoperative day until the end of the experiment, the time of severe rejection at day +7. Acute kidney allograft rejection led to alterations in the expression and activity of MMP. Overall MMP activity slightly increased despite severe destruction of kidney histology. The MMP inhibitor @entity11556 successfully inhibited MMP activity to a high extent. MMP expression did not show uniform findings, since acute rejection led to differential expression of @entity11017 and @entity6929 . During the rejection process, @entity6929 showed a small but significant increase, whereas @entity11017 production decreased substantially. Interestingly, @entity11556 was able to keep @entity644 at a low level in transplanted animals. In conclusion, MMP-especially @entity6929 -appear to represent new mediators involved in acute kidney transplant rejection.

title: Differential expression of XXXX / @entity6929 and potential benefit of an MMP inhibitor in experimental acute kidney allograft rejection.

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat strain', 'rats']

answer: @entity11017 :: (81686(Tax:10116),Gene) :: ['MMP-2']


abstract: In November 1984, due to an accident at a chemical plant, toxic @entity5497 gas spread into the town of Geneva, Switzerland, at concentrations over five times the maximal admissible concentration (MAC). Monitoring of atmospheric brome concentrations allowed the determination both of the duration of exposure and the geographical area concerned. Description of the immediate measures taken at the time of the accident illustrates how mass panic reactions can be generated or controlled, and clearly shows the vital importance of an effective communication network: it was lacking in this case and caused further insecurity for the population and isolation of the hospital. Immediate and systematic data collection enabled us to carry out an "acute" epidemiological survey of the accident. It is the first report of mass @entity5497 intoxication in the medical literature. 91 @entity1 with symptoms of @entity5497 exposure were seen in the outpatient and casualty departments of the cantonal Hospital, but the clinical course was mild and self-limited in nearly all cases. One @entity1 was admitted for 24 hours. The most common symptoms were upper respiratory tract symptoms, cough and @entity10 . In 20-30% of cases these pesisted for more than three days, and sometimes up to one month. Recording the location of @entity1 at the time when their first symptoms occurred made it possible to define the exposed area with precision. When the initial data collected in this "acute" fashion is reliable, it should be possible to undertake more elaborate epidemiological studies at a later stage if necessary.

title: [ XXXX cloud in Geneva. Epidemiologic study of the short-term effects on a population sample].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity5497 :: (MESH:D001966,Chemical) :: ['Bromine']


abstract: UNASSIGNED: Introduction: The beginning of the nano-era started with the appearance of artificial nanosized supramolecular systems called nanomaterials and nanoparticles (NPs). Areas covered: In the present review, we have analyzed the patents on @entity3151 -based nanomaterials ( @entity16820 , quantum dots [QDs], @entity15583 , liposomes, dendrimers, gold and @entity575 NPs) in biology and medicine. Their impact in treatment of @entity5 and @entity65 is discussed. Expert opinion: Liposomes and dendrimers had the highest number of biomedical patents. The third candidates were QDs and the fourth and fifth were gold and @entity575 NPs. @entity16820 and @entity505 nanotubes have the fewest applications in biology and medicine. Thus, our first conclusion was about the 'unifying nanotoxicology paradigm', that 'soft' NPs are significantly more biocompatible than 'hard' NPs. There has been a trend of these nanomaterials being applied in medicine drug and gene delivery, visualization of cells and pathologic processes, using them as antivirals and antimicrobials, contrast agents, antioxidants and photosensitizers. It was unexpected that no patents were found in which @entity3151 NPs were used in 3D printing of bones and other biological tissues. The conclusion reached is that nanomaterials are promising tools in future medical applications.

title: XXXX -containing nanoparticles: biomedical patents review.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer, viral infections']

entities_list: @entity16820 :: ('MESH:D037741', 'Chemical') :: ['fullerenes', 'Fullerenes']

entities_list: @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']

answer: @entity3151 :: (MESH:D010758,Chemical) :: ['Phosphorus']


abstract: PURPOSE: Carotid blowout syndrome due to @entity3538 in @entity11408 @entity1 with prior neck radiation is an uncommon but life-threatening complication. Concomitant @entity543 with @entity385 and carotid rupture from @entity2849 is rare. CASE REPORT: A 71-year-old @entity1 had a history of @entity11408 treated with radiation therapy 26 years ago. He was admitted to the hospital because of minor @entity385 and tarry stool. The carotid duplex sonography disclosed severe @entity75 in the proximal right internal carotid artery. A subsequent recurrent @entity64 on day three associated with nasal cavity bleeding resulted in an endotracheal intubation. Another episodic of @entity1415 occurred on day 10 caused @entity3485 shock. @entity3538 was found by emergent angiography and was immediately obliterated by endovascular treatment with microcoils and glue. CONCLUSION: Carotid blowout syndrome in @entity11408 @entity1 during acute @entity385 warrants further cervical angiographic study. Endovascular treatment provides immediate hemostasis and obliteration of @entity6455 @entity2849 .

title: Massive Epistaxis from Internal Carotid Pseudoaneurysm during Acute @entity385 in a XXXX with Nasopharyngeal Carcinoma.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['stenotic lesion']

entities_list: @entity1415 :: ('MESH:D004844', 'Disease') :: ['massive epistaxis']

entities_list: @entity3538 :: ('MESH:D002341', 'Disease') :: ['rupture of internal carotid artery pseudoaneurysm', 'Pseudoaneurysm of the left internal carotid artery']

entities_list: @entity3485 :: ('MESH:D020896', 'Disease') :: ['hypovolemic']

entities_list: @entity543 :: ('MESH:D016893', 'Disease') :: ['carotid stenosis']

entities_list: @entity2849 :: ('MESH:D017541', 'Disease') :: ['pseudoaneurysm']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity1 :: (9606,Species) :: ['Patient']


abstract: PURPOSE: Our goals are to establish an in vitro screening system and to evaluate a new approach in improving oral absorption of peptides and peptide-like drugs by overexpression of the @entity1 intestinal oligopeptide transporter ( @entity37537 ). This study characterizes the expression of @entity37537 in @entity1 intestinal Caco-2 cells, @entity35 intestinal epithelial cells (IEC-18), and @entity1 cervix epithelial cells (Hela) after adenoviral transduction. METHODS: A recombinant replication-deficient adenovirus carrying the @entity37537 gene was made and used as a vector for the expression of @entity37537 . The increase in the uptake permeability of @entity7265 and @entity36900 was determined. The effects of time, dose, apical pH, and substrate specificity were evaluated. RESULTS: A significant increase in the uptake permeability of @entity36900 and @entity7265 was found in all three cell lines after viral transduction. The increase of @entity36900 permeability in Hela. IEC-18, and Caco-2 cells was 85-, 46-, and 15-fold respectively. Immunoblotting using an antibody against @entity37537 detected high levels of a 85-98-kDa protein in all three infected cell lines. Substrate permeability was dependent on time of @entity281 , inward pH gradients, and multiplicity of @entity281 (MOI). @entity281 and lower @entity37537 expression were observed in differentiated Caco-2 cells. The uptake was inhibited by @entity9881 and @entity3405 antibiotics but not @entity1522 . CONCLUSIONS: @entity281 Hela cells displayed a pronounced level of @entity37537 expression with a low background and high specificity to @entity9881 . These features make this system a useful tool for screening of potential substrates. The success of overexpression of @entity37537 in Caco-2 and IEC-18 cells may lead to a novel approach in improving oral absorption of peptides and peptidornimetic drugs.

title: Overexpression of @entity1 intestinal oligopeptide transporter in XXXX cells via adenoviral transduction.

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity3405 :: ('CHEBI:35627', 'Chemical') :: ['beta-lactam']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['Adenoviral infected', 'infection', 'Decreased infectivity']

entities_list: @entity7265 :: ('MESH:D002506', 'Chemical') :: ['cephalexin']

entities_list: @entity9881 :: ('MESH:D004151', 'Chemical') :: ['dipeptides']

answer: @entity1 :: (9606,Species) :: ['mammalian']


abstract: @entity20377 continues to be a perplexing diagnostic and therapeutic problem for most ophthalmologists. However, thorough investigation, both systemic and ocular, can in most cases, establish either an environmental etiology or the nature of the heritable disorder. In cases with @entity262 and @entity20377 , the ophthalmologist should insure that each @entity1 obtains adequate consultation with other specialists in order that proper prophylactic and therapeutic measures are available. The @entity1614 , @entity7611 , and the @entity36640 together account for the majority of @entity3029 . Each of these requires a somewhat different therapeutic approach. @entity726 should be recognized as a frequent complication in each of these conditions but is most serious in the @entity36640 in which it often occurs early in life and remains unrecognized until serious damage has occurred. Because of the pupillary-block nature of the @entity726 in this condition, a prophylactic peripheral iridectomy must be seriously considered in every case while lens surgery should be undertaken if the @entity726 cannot be controlled by medical or surgical means. In @entity7611 , because of the potential vascular complications of general anesthesia, the ophthalmologist is often in a dilemma. The lens in this condition seems to be more mobile than in other @entity20377 and therefore likely to compromise vision earlier in life. However, due to the risk of vascular @entity715 , lens surgery should be delayed whenever possible until the @entity1 is old enough to tolerate local anesthesia. Likewise, @entity1 with the @entity1614 should be handled conservatively and, in general, function quite well simple with spectacle correction. Due to the high frequency of immediate surgical complications, it is advisable to avoid an open-sky technique to lens removal, using aspiration or a pars plana approach instead.

title: Differential diagnosis and treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity7611 :: ('MESH:D006712', 'Disease') :: ['homocystinuria']

entities_list: @entity1614 :: ('MESH:D008382', 'Disease') :: ['Marfan syndrome']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic disease']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['Glaucoma', 'glaucoma']

entities_list: @entity36640 :: ('MESH:D056846', 'Disease') :: ['Weill-Marchesani syndrome', 'Weill-Marchesani']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity20377 :: ('MESH:D004479', 'Disease') :: ['ectopia lentis', 'Ectopia lentis', 'ectopia lentis disorders']

entities_list: @entity3029 :: ('MESH:D004204', 'Disease') :: ['dislocated lenses']

answer: @entity3029 :: (MESH:D004204,Disease) :: ['dislocated lenses']


abstract: BACKGROUND/AIMS: Rituximab and glucocorticoids are a non-inferior alternative to @entity786 and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated @entity1333 (AAV) @entity1 with moderate @entity8 . The efficacy and safety of this approach in @entity1 with severe @entity8 are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in @entity1 with AAV and ANCA-negative @entity1333 presenting with severe @entity8 . METHODS: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. @entity1 with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of  <=20 ml/min/1.73 m(2) treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen @entity1 met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The secondary outcomes were eGFR at 6 months, @entity454 ( @entity454 ), survival rates and adverse events. RESULTS: All @entity1 were Caucasian, and 57% were male. The mean eGFR was 12 ml/min/1.73 m(2) at diagnosis. All @entity1 achieved remission with a median time to remission of 55 days. Seven @entity1 required dialysis at presentation of which 5 @entity1 recovered renal function and discontinued dialysis by 6-month follow-up. The mean eGFR for the 11 @entity1 without @entity454 who completed 6-month follow-up was 33 ml/min/1.73 m(2). Four @entity1 ultimately developed @entity454 , and one died during the follow-up period. CONCLUSION: @entity1 with AAV and severe @entity8 achieve high rates of remission and dialysis independence when treated with rituximab and glucocorticoids without @entity786 .    2015 S. Karger AG, Basel.

title: Treatment of Severe XXXX in ANCA Positive and Negative Small @entity1333 with Rituximab.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment', 'renal disease']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']

answer: @entity8 :: (MESH:D007674,Disease) :: ['Renal Disease']


abstract: Three lactating Holstein @entity291 , averaging 510 kg and fitted with T-type duodenal cannulae in the proximal duodenum, were in a 3 X 3 Latin-square experiment to measure digestion in forestomachs and whole tract of feed @entity1568 and neutral detergent fiber components as influenced by frequency of feeding. @entity291 were fed one diet containing 65% chopped grass legume hay, 26% cracked @entity4336 , and 8% @entity1460 meal. Mixed ration was fed either once daily, four times daily, or the concentrate portion of the diet was fed once daily and the forage portion four times. Ytterbium, as @entity72434 , was included with diets to allow calculation of flow rates of @entity62 . Assayed ratios of @entity1568 to @entity6135 in ruminal bacteria and duodenal digesta or fecal bacteria and feces were used to calculate duodenal and fecal bacterial @entity1568 flows respectively. Ratios of @entity1568 to @entity6135 in ruminal and fecal bacteria averaged 4.15 and 2.38 g/mmol. Apparent digestibility of organic matter in the forestomachs and whole tract averaged 43.7 and 66.4%. Forestomach and whole tract digestibility of cellulose, hemicellulose, and lignin averaged 56.1, 52.0, 14.7, and 58.7, 58.5, and 16.8. Bacterial @entity1568 flows averaged 255 and 91 g/day at the duodenum and in the feces. Bacterial @entity1568 yield in the rumen averaged 36.6 g/kg organic matter apparently digested in the forestomachs. Frequency of feeding had no effect on almost all measures and components of rumen and whole tract metabolism and digestion. For these intakes, frequency of feeding had little effect on feed intake and nutrient utilization.

title: Forestomach and whole tract digestibility for lactating dairy XXXX as influenced by feeding frequency.

entities_list: @entity6135 :: ('MESH:D003960', 'Chemical') :: ['diaminopimelic acid']

entities_list: @entity72434 :: ('MESH:C044841', 'Chemical') :: ['ytterbium chloride']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['duodenal and fecal dry matter']

answer: @entity291 :: (9913,Species) :: ['cows']


abstract: AIM: To determine whether short-term intensive group-based therapy combining modified constraint-induced movement therapy and bimanual therapy (hybrid- @entity6481 ) is more effective than an equal total dose of distributed individualized occupational therapy (standard care) on upper limb motor and individualized outcomes. METHOD: Fifty-three @entity1 with @entity306 (69% males; mean age 7y 10mo, SD 2y 4mo; Manual Ability Classification System level I, n=24; level II, n=23) were randomly allocated, and 44 received either hybrid- @entity6481 (n=25) or standard care (n=19). Standard care comprised six weekly occupational therapy sessions and a 12-week home programme. Outcomes were assessed at baseline, 13  weeks, and 26  weeks after treatment. RESULTS: Groups were equivalent at baseline. Standard care achieved greater gains on satisfaction with occupational performance after intervention (estimated mean difference -1.2, 95% CI -2.2 to -0.1; p=0.04) and Assisting Hand Assessment at 26  weeks (estimated mean difference 3.1, 95% CI 0.2-6.0; p=0.04). Both groups demonstrated significant improvements in dexterity of the @entity3140 , and bimanual and occupational performance over time. The differences between groups were not clinically meaningful. INTERPRETATION: There were no differences between the two models of therapy delivery. Group-based intensive camps may not be readily available; however, individualized standard care augmented with a home programme may offer an effective alternative but needs to be provided at a sufficient dose.

title: Randomized comparison trial of density and context of upper limb intensive group versus individualized occupational therapy for @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity3140 :: ('MESH:D038062', 'Disease') :: ['impaired upper limb']

entities_list: @entity306 :: ('MESH:D002547', 'Disease') :: ['unilateral cerebral palsy']

answer: @entity306 :: (MESH:D002547,Disease) :: ['unilateral cerebral palsy']


abstract: PURPOSE: Intravaginal high-dose-rate brachytherapy is an effective adjuvant treatment for localized @entity1204 . However, relatively little is known about risk factors of post-treatment vaginal @entity850 (VS). METHODS AND MATERIALS: We included @entity1 treated with brachytherapy for @entity1204 from September 2011 to January 2014 with at least 3 months of followup. @entity1 who received external beam radiation therapy were excluded. VS was prospectively graded at each followup visit per Common Terminology Criteria for Adverse Events, version 4.03.   (2) and t test analyses were used to assess the association of VS with various @entity1 , @entity5 , treatment, and post-treatment factors. Multivariable logistic regression analysis was used to identify independent predictors of VS Grade >= 1 and >= 2. RESULTS: All 101 @entity1 were disease free at last followup. Mean followup was 12.9 months (range, 3-34). Highest VS grades were zero in 67%, one in 26%, two in 6%, and three in 1%. Borderline significant variables associated with Grade >= 1 VS included @entity8376 , proportion of vagina treated, and total dose. Dilator use was significantly associated with Grade >= 2. Multivariable analysis revealed that proportion of vagina treated >60% (odds ratio [OR], 3.48; p = 0.009) and total dose >14 Gy (OR, 4.27; p = 0.015) were independent predictors of Grade >= 1 VS, and lack of consistent dilator use was an independent predictor of Grade >= 2 VS (OR, 5.60; p = 0.047). CONCLUSIONS: @entity1 treated with a higher total dose to a larger proportion of the vagina were more likely to develop Grade >= 1 VS. Consistent dilator use may also be protective against Grade >= 2 VS.

title: Predictors of vaginal @entity850 after intravaginal high-dose-rate brachytherapy for XXXX .

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity8376 :: ('MESH:D014625', 'Disease') :: ['vagina length']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity1204 :: (MESH:D016889,Disease) :: ['endometrial carcinoma']


abstract: Nodal marginal zone @entity1892 (NMZBL) occasionally represents prominent plasma cell differentiation. Recently, primary lymph node @entity6872 has been suggested to represent an extremely plasmacytic differentiation of NMZBL. We here report a case of NMZBL showing histological features resembling @entity6872 arising from a plasma cell variant of localized @entity12692 (PCLCD). The @entity1 was a 69-year-old Japanese female with a 20-year history of a right inguinal mass. Histologically, a prominent proliferation of plasma cells occupied the interfollicular area of the central portion of the lymph node, whereas @entity1073 ( @entity1073 ) cells were the main cellular component in the peripheral portion of the lymph node. Although most of the plasma cells were mature 'Marshalko-type', occasional atypical forms with enlarged nuclei were also present. The majority of the lymphoid follicles had @entity3202 or regressive germinal centers. A few lymphoid follicles were colonized by @entity1073 cells. Immunohistochemistry study revealed that both plasma cells and some @entity1073 cells had a monotypic intracytoplasmic lambda light chain. When monoclonal plasma cell infiltration is observed in PCLCD, the light chains are mostly restricted to the lambda chain. This case suggests that some plasma cell-containing @entity5 arising from PCLCD may represent a variant of NMZBL.

title: Nodal marginal zone @entity1892 resembling XXXX arising from a plasma cell variant of localized @entity12692 : a case report.

entities_list: @entity6872 :: ('MESH:D010954', 'Disease') :: ['plasmacytoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity12692 :: ('MESH:D005871', 'Disease') :: ["Castleman's disease"]

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma']

entities_list: @entity1073 :: ('MESH:D020522', 'Disease') :: ['CCL', 'centrocyte-like']

answer: @entity6872 :: (MESH:D010954,Disease) :: ['plasmacytoma']


abstract: @entity1 @entity63416 ( @entity63416 ) is a recently discovered member of the tissue kallikrein family of secreted @entity563 proteases, which includes @entity16914 / @entity1486 , the @entity5 biomarker to date. Given that @entity63416 is hormonally regulated, differentially expressed in endocrine-related @entity5 , and a prognostic marker for @entity5344 at the mRNA level, we hypothesize that its encoded protein, @entity6881 , like @entity16914 / @entity1486 , may constitute a new biomarker for endocrine-related @entity5 . The objective of this study was to generate immunological reagents for @entity6881 , to develop an ELISA and immunohistochemical techniques to study its expression in normal and cancerous tissues and biological fluids. Recombinant @entity6881 was produced in @entity10056 , purified by affinity chromatography, and injected into @entity19 and rabbits for polyclonal antibody generation. Using the @entity19 and rabbit antisera, a sandwich-type immunofluorometric ELISA and immunohistochemical methodologies were developed for @entity6881 . The ELISA was sensitive (detection limit of 0.1 micro g/liter), specific for @entity6881 , linear from 0 to 20 micro g/liter with between-run and within-run coefficients of variation of <10%. @entity6881 was quantified in @entity1 tissue extracts and biological fluids. Highest levels were observed in the breast, skin, prostate, seminal plasma, and amniotic fluid, with almost undetectable levels in normal serum. @entity6881 concentration was higher in 40% of @entity43 tissues compared with normal ovarian tissues. Serum @entity6881 levels were elevated in a proportion of @entity1 with ovarian (65%) and breast (40%) @entity5 . Immunohistochemical analyses indicated strong cytoplasmic staining of @entity6881 by the epithelial cells of normal and malignant skin, ovary, breast, and testis. In conclusion, we report the first ELISA and immunohistochemical assays for @entity6881 and describe its distribution in tissues and biological fluids. Our preliminary data indicate that @entity6881 is a potential biomarker for @entity5344 .

title: XXXX kallikrein 14: a new potential biomarker for @entity5344 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'Human']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity5344 :: ('MESH:D061325', 'Disease') :: ['breast and ovarian cancer', 'breast and ovarian cancers']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'best cancer', 'malignancies']

entities_list: @entity10056 :: ('4922', 'Species') :: ['Pichia pastoris']

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: OBJECTIVE: The purpose of this study was to analyze modalities of the transition from pediatric to @entity302 care and @entity1 ' acquisition of autonomy. METHOD: This study was conducted using semidirected interviews composed of three major parts: the @entity1 's criteria of transition toward adult healthcare (factors taken into account, anticipation, the @entity1 's opinion, etc.), conditions (teamwork with the neurologists, transmission of the medical record, continuity of health care, etc.), and the role played by social workers and psychologists. We interviewed 10  doctors belonging to six major Parisian hospital units involved in the monitoring of @entity1 and adolescents with @entity302 and working in Pediatric Neurology Departments of the   le-de-France region. RESULTS: For most of the doctors, reaching 18 years of age was the major argument taken into account to consider transition to adult care. According to the doctors interviewed, parents are generally worried when their @entity1 has to find another doctor (7/10). According to eight out of 10  doctors, the neurologist is selected to take over. The doctors recognize the importance of psychologists and social workers even if they are not always included. The process by which the @entity1 gains autonomy depends a great deal on the role played by the pediatricians and parents, although some parents are very protective. This behavior weakens the @entity1 's capacity for autonomy and it varies according to the degree of his or her physical and/or @entity16 . Furthermore, developing autonomy requires interdisciplinary work that is not yet fully in place. CONCLUSION: The lack of structures well-adapted to the uniqueness of each @entity1 and the lack of coordination between the various institutions do not favor the acquisition of autonomy. A network that could efficiently respond to the needs of @entity302 @entity1 as well as medical care tailored to adolescents would be the answer to this dilemma.

title: [A difficult transition from childhood to adult healthcare: The case of XXXX .]

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'child']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disabilities']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['adult epilepsy', 'epileptic', 'epilepsy']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: An 80-year-old @entity1 , who was followed as an A-bomb victim, was diagnosed to have advanced @entity1086 with liver @entity3 on December, 2005. Due to her advanced age, her previous doctor recommended the best supportive care. Therefore, her general condition was good, so we decided to treat her with @entity900 , @entity1259 and continuous infusion of @entity1487 (CEF therapy). She was given @entity1487 500 mg/body per day via continuous infusion on days 1 to 5, @entity900 50mg body and @entity1259 20mg body on day 1 every 28 days, and these dosages have been reduced. CEF therapy was started from February, 2007. @entity75 and liver @entity3 decreased remarkably after completion of 2 cycles, and we judged it as a complete response. After 10 cycles, lung @entity3 was found by CT scan in August, 2007. We tried chemotherapy with @entity136 as a second-line treatment. The result of @entity136 was again a progressive disease, so we switched her regimen to S-1 as a third-line treatment on January, 2008. Chemotherapy is continued by the outpatient care now, 25 months after the medical treatment started. The present result suggests that CEF therapy may be useful for metastatic @entity1086 .

title: [Elderly @entity1 with metastatic @entity1086 treated by XXXX , @entity1259 and continuous infusion @entity1487 ].

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Primary lesion']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1086 :: ('MESH:D005706', 'Disease') :: ['gallbladder cancer']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: BACKGROUND: Nearly 30% of @entity1 with @entity302 continue to have @entity410 in spite of using several antiepileptic drug (AED) regimens. Such @entity1 are regarded as having refractory, or uncontrolled, @entity302 . No definition of uncontrolled, or medically refractory, @entity302 has been universally accepted, but for the purposes of this review, we will consider @entity410 as drug resistant if they have failed to respond to a minimum of two AEDs. It is believed that early surgical intervention may prevent @entity410 at a younger age, which, in turn, may improve the intellectual and social status of @entity1 . Many types of surgery are available for treatment of @entity302 ; one such procedure is known as subpial transection. OBJECTIVES: To determine the benefits and adverse effects of subpial transection for partial-onset @entity410 and generalised @entity410 in @entity1 and adults. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialised Register (29 June 2015), the Cochrane Central Register of Controlled Trials (CENTRAL; May 2015, Issue 5) and MEDLINE (1946 to 29 June 2015). We imposed no language restrictions. SELECTION CRITERIA: We considered all randomised and quasi-randomised parallel-group studies, whether blinded or non-blinded. DATA COLLECTION AND ANALYSIS: Two review authors (BK and SR) independently screened trials identified by the search. The same two review authors planned to independently assess the methodological quality of studies. When studies were identified for inclusion, one review author would have extracted the data, and the other would have verified the data. MAIN RESULTS: We found no relevant studies. AUTHORS' CONCLUSIONS: We found no evidence to support or refute use of subpial transection surgery for @entity1 with medically @entity302 . Well-designed randomised controlled trials are needed to guide clinical practice.

title: Subpial transection surgery for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures', 'tonic-clonic seizures']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['refractory epilepsy', 'epilepsy']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: UNASSIGNED: There are limited data to guide the choice of @entity34 ( @entity34 ) regimen before autologous hematopoietic cell transplantation (AHCT) for @entity1 with Hodgkin ( @entity1733 ) and @entity1893 ( @entity1893 ). We studied 4917 @entity1 ( @entity1893 , n  = 3905; @entity1733 , n  = 1012) who underwent AHCT from 1995 to 2008 using the most common @entity34 platforms: carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) (n  = 1730); cyclophosphamide, BCNU, and etoposide (CBV) (n  = 1853); busulfan and cyclophosphamide (BuCy) (n  = 789); and @entity348 ( @entity348 )-containing treatment (n  = 545). CBV was divided into CBV(high) and CBV(low) based on BCNU dose. We analyzed the impact of regimen on development of @entity358 ( @entity358 ), transplantation-related mortality (TRM), and progression-free and overall survival. The 1-year incidence of @entity358 was 3% to 6% and was highest in recipients of CBV(high) (hazard ratio [HR], 1.9) and @entity348 (HR, 2.0) compared with BEAM. One-year TRM was 4% to 8%, respectively, and was similar between regimens. Among @entity1 with @entity1893 , there was a significant interaction between histology, @entity34 regimen, and outcome. Compared with BEAM, CBV(low) (HR, .63) was associated with lower mortality in @entity706 (P < .001), and CBV(high) (HR, 1.44) was associated with higher mortality in diffuse large B cell lymphoma (P  = .001). For @entity1 with @entity1733 , CBV(high) (HR, 1.54), CBV(low) (HR, 1.53), BuCy (HR, 1.77), and @entity348 (HR, 3.39) were associated with higher mortality compared with BEAM (P < .001). The impact of specific AHCT regimen on post-transplantation survival is different depending on histology; therefore, further studies are required to define the best regimen for specific diseases.

title: Impact of Conditioning Regimen on Outcomes for XXXX with @entity706 Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['follicular lymphoma']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['IPS', 'idiopathic pulmonary syndrome']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['total body irradiation', 'TBI']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', 'non-Hodgkin lymphoma']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['high-dose therapy', 'HDT']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: INTRODUCTION: Historically, federal funding streams to address @entity5 and @entity286 use have been provided separately to state health departments. This study aims to document the impact of a recent focus on coordinating @entity102 efforts through collaboration between the 2 programs. METHODS: Through a case-study approach using semistructured interviews, we collected information on the organizational context, infrastructure, and interaction between @entity5 and @entity286 control programs in 6 states from March through July 2012. Data were analyzed with NVivo software, using a grounded-theory approach. RESULTS: We found between-program activities in the state health department and coordinated implementation of interventions in the community. Factors identified as facilitating integrated interventions in the community included collaboration between programs in the strategic planning process, incorporation of one another's priorities into state strategic plans, co-location, and leadership support for collaboration. Coalitions were used to deliver integrated interventions to the community. Five states perceived high staff turnover as a barrier to collaboration, and all 5 states felt that federal funding requirements were a barrier. CONCLUSIONS: @entity5 and @entity286 programs are beginning to implement integrated interventions to address @entity102 . Findings can inform the development of future efforts to integrate program activities across @entity102 prevention efforts.

title: Factors involved in the collaboration between the national XXXX control programs and @entity286 control programs: a qualitative study of 6 States, United States, 2012.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer', 'cancer']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

answer: @entity5 :: (MESH:D009369,Disease) :: ['comprehensive cancer']


abstract: @entity219 , an essential trace element, is involved in many important physiological processes. Cell responses to @entity219 stress show time-dependent effects besides concentration-dependence and tissue-specificity. Herein, we investigated the time-dependent differential expression of the proteome in A549 cells after administered with @entity5937 for both 9 and 24 h using 2DE. 123 differentially expressed protein spots were detected, most of which were up-regulated by @entity8862 treatment. Interestingly, 49 proteins exhibited significant differential expression repeatedly during these two treatment periods, and moreover showed a conserved change with different ratios and four time-dependent expression patterns. Pattern 1 (up-regulated with rapid initial induction and subsequent repression) and pattern 4 (down-regulated with steady repression) were the predominant expression patterns. The abundances of the proteins in patterns 1 and 4 after 24 h of @entity219 treatment are always lower than that after 9 h, indicating that exogenous @entity219 reduced the expression of proteins in cells after 24 h or longer. Importantly, these findings could also reflect the central challenge in detecting @entity219 homeostasis proteins by 2DE or other high throughput analytical methods resulting from slight variation in protein expression after certain durations of exogenous @entity219 treatment and/or low inherent protein content in cells. These time-dependent proteome expression patterns were further validated by measuring dynamic changes in protein content in cells and in expression of two proteins using the Bradford method and western blotting, respectively. The time-dependent changes in total @entity219 and free @entity8862 ion contents in cells were measured using ICP- @entity15 and confocal microscopy, respectively. The kinetic process of @entity219 homeostasis regulated by muffling was further revealed. In addition, we identified 50 differentially expressed proteins which are predominantly involved in metabolic process, cellular process or developmental process, and function as binding, catalytic activity or structural molecule activity. This study further elucidates our understanding of dynamic nature of the cellular response to @entity219 stress and the mechanism of @entity219 homeostasis.

title: The Kinetic Response of the Proteome in A549 Cells Exposed to XXXX Stress.

answer: @entity5937 :: (CHEBI:35176,Chemical) :: ['ZnSO4']